Marksans Pharma Limited (NSE:MARKSANS)
India · Delayed Price · Currency is INR 309.15
+5.40 (1.78%)
Nov 9, 2026, 12:25 PM IST
Marksans Pharma Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Operating Revenue | 33,915 | 29,509 | 26,228 | 21,774 | 18,521 | 14,908 |
| 33,915 | 29,509 | 26,228 | 21,774 | 18,521 | 14,908 | |
Revenue Growth | 24.20% | 12.51% | 20.46% | 17.56% | 24.23% | 8.33% |
Cost of Revenue | 15,010 | 13,379 | 11,981 | 10,740 | 9,401 | 7,295 |
Gross Profit | 18,905 | 16,131 | 14,247 | 11,034 | 9,120 | 7,613 |
Selling, General & Admin | 4,694 | 4,350 | 3,620 | 3,059 | 2,523 | 2,250 |
Other Operating Expenses | 6,372 | 5,769 | 5,300 | 3,389 | 3,202 | 2,774 |
Operating Expenses | 12,122 | 11,105 | 9,754 | 7,191 | 6,243 | 5,472 |
Operating Income | 6,783 | 5,026 | 4,493 | 3,843 | 2,877 | 2,141 |
Interest Expense | -260.75 | -241.25 | -116.6 | -112.03 | -60.96 | -57.4 |
Interest & Investment Income | 276.78 | 276.78 | 301.97 | 337.87 | 120.37 | 59.73 |
Currency Exchange Gain (Loss) | 500.95 | 500.95 | 193.11 | 82.4 | 397.77 | 205.79 |
Other Non Operating Income (Expenses) | 195.13 | 31.72 | 138.52 | 82.1 | 44.67 | 124.79 |
EBT Excluding Unusual Items | 7,496 | 5,594 | 5,010 | 4,233 | 3,379 | 2,474 |
Gain (Loss) on Sale of Investments | 12.27 | 12.27 | 6.94 | 0.52 | - | - |
Gain (Loss) on Sale of Assets | -0.64 | -0.64 | -0.33 | 0.94 | -2.64 | - |
Other Unusual Items | -0.17 | -0.17 | 22.75 | - | - | - |
Pretax Income | 7,507 | 5,606 | 5,040 | 4,235 | 3,377 | 2,475 |
Income Tax Expense | 1,850 | 1,405 | 1,213 | 1,086 | 723.32 | 606.97 |
Earnings From Continuing Operations | 5,657 | 4,201 | 3,826 | 3,149 | 2,653 | 1,868 |
Minority Interest in Earnings | -58.43 | -21.64 | -20.44 | -11.95 | 9.87 | - |
Net Income | 5,598 | 4,179 | 3,806 | 3,137 | 2,663 | 1,868 |
Net Income to Common | 5,598 | 4,179 | 3,806 | 3,137 | 2,663 | 1,868 |
Net Income Growth | 59.19% | 9.81% | 21.32% | 17.80% | 42.55% | -21.68% |
Shares Outstanding (Basic) | 453 | 453 | 453 | 453 | 415 | 409 |
Shares Outstanding (Diluted) | 453 | 453 | 453 | 453 | 415 | 409 |
Shares Change | -0.06% | - | - | 9.09% | 1.49% | - |
EPS (Basic) | 12.37 | 9.22 | 8.40 | 6.92 | 6.41 | 4.56 |
EPS (Diluted) | 12.35 | 9.22 | 8.40 | 6.92 | 6.41 | 4.56 |
EPS Growth | 59.26% | 9.79% | 21.36% | 7.96% | 40.44% | -21.68% |
Additional Metrics
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Free Cash Flow | 6,010 | 3,276 | 337.45 | 215.69 | 1,838 | 529.27 |
Free Cash Flow Per Share | 13.27 | 7.23 | 0.74 | 0.48 | 4.42 | 1.29 |
Dividend Per Share | - | 0.900 | 0.800 | 0.600 | 0.500 | 0.250 |
Dividend Growth | - | 12.50% | 33.33% | 20.00% | 100.00% | 0% |
Gross Margin | 55.74% | 54.66% | 54.32% | 50.67% | 49.24% | 51.07% |
Operating Margin | 20.00% | 17.03% | 17.13% | 17.65% | 15.53% | 14.36% |
Profit Margin | 16.51% | 14.16% | 14.51% | 14.41% | 14.38% | 12.53% |
Free Cash Flow Margin | 17.72% | 11.10% | 1.29% | 0.99% | 9.92% | 3.55% |
EBITDA | 7,473 | 5,646 | 5,054 | 4,337 | 3,203 | 2,405 |
EBITDA Margin | 22.03% | 19.13% | 19.27% | 19.92% | 17.30% | 16.13% |
D&A For EBITDA | 689.36 | 619.78 | 560.56 | 494.18 | 326.09 | 263.46 |
EBIT | 6,783 | 5,026 | 4,493 | 3,843 | 2,877 | 2,141 |
EBIT Margin | 20.00% | 17.03% | 17.13% | 17.65% | 15.53% | 14.36% |
Effective Tax Rate | 24.65% | 25.06% | 24.08% | 25.65% | 21.42% | 24.52% |
Revenue as Reported | 34,904 | 30,335 | 26,892 | 22,278 | 19,115 | 15,327 |